Home › Glomerulonephritis › NCT07431931
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria - Phase 2: A Quality Improvement Project
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adults aged ≥18 years * Patients receiving care from any Geisinger primary care provider (record of an encounter with a Geisinger PCP within the last 2 years from date of survey implementation) * Patients with high-risk glomerulonephritis features i.e. positive test results for hematuria (urine dipstick result with blood 1+ or greater) and proteinuria (2+ or 3+ protein on dipstick or ACR≥300 mg/g or PCR ≥500 mg/g) collected within 12 months of index date. Exclusion Criteria: * Patients with a nephrologist appointment in the last 12 months before the index date * Patients with a prior appointment with a nephrologist within the last 2 years before the positive urinalysis test for hematuria (1+ or greater) * Patients with a history of glomerulonephritis and/or kidney failure (dialysis or eGFR \< 15 mL/min/1.73m2, or kidney transplantation) at any time during the baseline * Patients receiving palliative care at any time during the baseline
About the study
The purpose of the study is to evaluate prospectively the impact of an electronic health record (EHR) alert on primary care providers' (PCP) referral to Nephrology of Geisinger patients with high risk signs (blood and protein in the urine) of glomerulonephritis. This will help quantify the relative effectiveness of EHR alerts on PCPs' referral patterns.
What is being tested
- Electronic Health Record alert (other)
Sponsor: Geisinger Clinic · Participants: 1,200 · Started: 2026-11
Contact the study team
- Alexander Chang, MD · Phone: 570-214-3156
Official record on ClinicalTrials.gov — NCT07431931
Locations in the U.S.
| Pennsylvania | Geisinger Medical Center, Danville |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.